Bhat, Yaqoob
Dixit, Anand
Mistri, Amit
Patel, Bhavini
Quoraishi, Sadat Haider
Uprichard, James http://orcid.org/0000-0001-7364-346X
Funding for this research was provided by:
Daiichi-Sankyo UK
Article History
Received: 29 April 2019
Accepted: 14 November 2019
First Online: 29 November 2019
Ethics approval and consent to participate
: Research ethics committee (REC) approval for this study has been obtained (NHS Health Research Authority London - South East Research Ethics Committee; REC reference: 18/LO/1923 [03 January 2019]). All patients will provide written informed consent to participate in the study.
: YB: Honoraria and conference support: Daiichi-Sankyo, BMS, Pfizer. AD: Scientific advisory boards: Boehringer-Ingelheim, Bayer; Honoraria and conference support: Boehringer-Ingelheim, Bayer, Daiichi-Sankyo, BMS, Pfizer. AM: honoraria for educational talks and grants to support conference attendance from Bayer plc, BMS-Pfizer, Boehringer-Ingelheim, and Daiichi-Sankyo, all companies manufacturing direct oral anticoagulants. BP: None. SHQ: is an employee of Daiichi Sankyo UK Ltd. JU: Scientific advisory boards: Bayer, Leo Pharma, Vifor Pharma, Portola, Octapharma; Speaker bureau: Bayer, Pfizer, Bristol-Myers Squibb, Octapharma, Shire, Vifor Pharma, Daiichi-Sankyo; Clinical trials: Portola, Bayer, Boehringer-Ingelheim, Baxalta, Daiichi-Sankyo; Travel support: Bayer, Baxter, Pfizer. Commercial funding for this study is provided by Daiichi-Sankyo UK Ltd.